NORTHERA (droxidopa): Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See NDA 203202's history or Chelsea Therapeutics, Inc.'s company page.
On Mar 28, 2012, FDA declined to approve NORTHERA (droxidopa) (NDA 203202) from Chelsea Therapeutics, Inc. in its present form, citing clinical/ statistical, labeling, risk evaluation and mitigation strategy requirements. The application was later approved.
- Letter date: Mar 28, 2012
- Application: NDA 203202
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDAYou submitted the results of 3 clinical trials (studies 301, 302, and 303) to support the efficacy of droxidopa for the treatment of neurogenic orthostatic hypotension (NOH). Study 302 was conducted first and was a negative study, based on the primary endpoint...… openFDA did not return the full text just now. Open it in the letter search.
Record
- Company
- Chelsea Therapeutics, Inc.
- Application
- NDA 203202
- Status in openFDA
- Approved
- Review division
- Office of Drug Evaluation I
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters